Novo Nordisks scientists continued to refine GLP-1 analogs, eventually developing semaglutide , which was first released as Ozempic for diabetes and later approved as Wegovy for obesity
To maximize results, we often recommend:Peptides work best when your daily habits support your physiology
We have mountains of evidence that lifestyle-based weight-loss interventions are not effective in the long term for the overwhelming majority of people
Unlike quick, transactional telemedicine appointments, these sessions are designed to be thorough
Ozempic often used off-label) Tirzepatide (Zepbound / Mounjaro) a dual GLP-1/GIP agonist that tends to produce even greater weight loss Liraglutide (Saxenda) Originally developed for Type 2 diabetes, these medications received Health Canada approval for chronic weight management in adults with a BMI 30, or BMI 27 with at least one weight-related condition (such as hypertension, dyslipidemia, or obstructive sleep apnea)
It's important to prioritize consultations with healthcare professionals